<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02784171</url>
  </required_header>
  <id_info>
    <org_study_id>I227</org_study_id>
    <secondary_id>2016-002286-60</secondary_id>
    <secondary_id>IFCT-1901</secondary_id>
    <nct_id>NCT02784171</nct_id>
  </id_info>
  <brief_title>Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma</brief_title>
  <official_title>A Phase II/III Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Canadian Cancer Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute, Naples</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Intergroupe Francophone de Cancerologie Thoracique</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Canadian Cancer Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pembrolizumab is a new type of drug for mesothelioma (immunotherapy). Laboratory tests show&#xD;
      that this drug works by helping improve the body's immune response to help fight cancer.&#xD;
      Pembrolizumab may help the immune system to recognize cancer cells and slow down the growth&#xD;
      and/or spreading of cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to find out what effects a new drug, pembrolizumab has on this&#xD;
      type of cancer and if it can offer better results than standard pemetrexed and platinum-based&#xD;
      chemotherapy alone. This study will also look at side effects and how the treatments impact&#xD;
      quality of life&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 7, 2016</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase II: Progression free survival measured as time from randomization to first observation of objective disease relapse or progression</measure>
    <time_frame>32 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase III: Overall Survival defined as time from randomization to the date of death from any cause</measure>
    <time_frame>32 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number and severity of adverse events</measure>
    <time_frame>32 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>32 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life using EORTC QLQ-C30</measure>
    <time_frame>32 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response rate compared using Fisher's exact test</measure>
    <time_frame>32 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">520</enrollment>
  <condition>Mesothelioma</condition>
  <arm_group>
    <arm_group_label>Arm A - Cisplatin/Pemetrexed</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pemetrexed 500 mg/m2 IV Day 1 every 21 days for 6 cycles Cisplatin 75 mg/m2 IV Day 1 every 21 days for 6 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B - Cisplatin/Pemetrexed/Pembrolizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pembrolizumab 200 mg* IV Day 1 over 30 min every 21 days for a total of 2 years Pemetrexed 500 mg/m2 IV Day 1 every 21 days for 6 cycles Cisplatin 75 mg/m2 IV Day 1 every 21 days for 6 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C - Pembrolizumab (Phase II only)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pembrolizumab 200 mg* IV 30 min Day 1 every 21 days for a total of 2 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <arm_group_label>Arm A - Cisplatin/Pemetrexed</arm_group_label>
    <arm_group_label>Arm B - Cisplatin/Pemetrexed/Pembrolizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <arm_group_label>Arm A - Cisplatin/Pemetrexed</arm_group_label>
    <arm_group_label>Arm B - Cisplatin/Pemetrexed/Pembrolizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <arm_group_label>Arm B - Cisplatin/Pemetrexed/Pembrolizumab</arm_group_label>
    <arm_group_label>Arm C - Pembrolizumab (Phase II only)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have histologically confirmed malignant pleural mesothelioma. Patients&#xD;
             must be eligible to receive standard chemotherapy with pemetrexed and cisplatin and&#xD;
             have no contraindications to standard chemotherapy.&#xD;
&#xD;
          -  Patients must have unresectable advanced and/or metastatic disease, incurable by&#xD;
             standard therapies.&#xD;
&#xD;
          -  All patients must have a cellular tumour block from their primary or metastatic tumour&#xD;
             available and consent to release the block/recently cut slides for correlative&#xD;
             analyses (See Section 11.0) and the centre/pathologist must have agreed to the&#xD;
             submission of the specimen(s).&#xD;
&#xD;
          -  Presence of radiologically documented disease. At least one site of disease must be&#xD;
             unidimensionally measurable as follows:&#xD;
&#xD;
               -  CT scan (with slice thickness of ≤ 5 mm): ≥ 10 mm --&gt; longest diameter&#xD;
&#xD;
               -  Physical exam (using calipers): ≥ 10 mm&#xD;
&#xD;
               -  Lymph nodes by CT scan ≥ 15 mm --&gt; measured in short axis&#xD;
&#xD;
          -  All radiology studies must be performed within 21 days prior to registration&#xD;
             (exception: within 28 days if negative).&#xD;
&#xD;
          -  Age ≥ 18 years.&#xD;
&#xD;
          -  ECOG performance status 0 or 1.&#xD;
&#xD;
        Previous Therapy&#xD;
&#xD;
        Cytotoxic Chemotherapy:&#xD;
&#xD;
          -  Patients must not have received prior chemotherapy for any stage of&#xD;
             advanced/metastatic disease.&#xD;
&#xD;
          -  Patients who received previous (neo)adjuvant cisplatin-based systemic chemotherapy&#xD;
             must have received the last dose of chemotherapy at least 12 months before&#xD;
             registration. Please contact CCTG PRIOR to randomization for such patients.&#xD;
&#xD;
        Other Anti-Cancer Therapy:&#xD;
&#xD;
          -  Patients may not have received targeted small molecule therapy, immunotherapies and&#xD;
             viral therapies, biologic therapies and angiogenesis inhibitors for&#xD;
             advanced/metastatic disease, or any prior immunotherapy for any stage of disease.&#xD;
&#xD;
        Radiation:&#xD;
&#xD;
          -  Patients may have had prior radiation therapy, but NOT to the thorax unless clear&#xD;
             disease progression has been demonstrated and confirmed with CCTG. A minimum of 28&#xD;
             days must have elapsed between the end of radiotherapy and registration onto the&#xD;
             study. Radiation must have involved &lt; 30% of functioning bone marrow and there must be&#xD;
             measurable disease outside the previously irradiated area (patients whose sole site of&#xD;
             disease (for example pleural rind) is in a previously irradiated area are ineligible&#xD;
             UNLESS there is evidence of progression, or new lesions have been documented, in the&#xD;
             irradiated field). Please contact CCTG PRIOR to randomization if the patient has&#xD;
             received prior thoracic radiation. Patients must have recovered from any acute toxic&#xD;
             effects from radiation prior to registration.&#xD;
&#xD;
        Previous Surgery:&#xD;
&#xD;
          -  Previous major surgery is permitted provided that it has been at least 28 days prior&#xD;
             to patient registration and that wound healing has occurred.&#xD;
&#xD;
          -  Lab Requirements:&#xD;
&#xD;
               -  Absolute neutrophils ≥ 1.5 x 10^9/L&#xD;
&#xD;
               -  Platelets ≥ 100 x 10^9/L&#xD;
&#xD;
               -  Hemoglobin ≥ 90 g/L&#xD;
&#xD;
               -  Bilirubin ≤ 1.5 x ULN (upper limit of normal)&#xD;
&#xD;
               -  AST and ALT ≤ 2.5 x ULN&#xD;
&#xD;
               -  Serum creatinine &lt; 1.25 x ULN or Creatinine clearance ≥ 50 mL/min&#xD;
&#xD;
          -  Patient consent must be appropriately obtained in accordance with applicable local and&#xD;
             regulatory requirements.&#xD;
&#xD;
          -  Patients must be accessible for treatment, response assessment and follow-up. Patients&#xD;
             registered on this trial must be treated and followed at the participating centre.&#xD;
&#xD;
          -  In accordance with CCTG policy, protocol treatment is to begin within 2 working days&#xD;
             of patient randomization.&#xD;
&#xD;
          -  Women/men of childbearing potential must have agreed to use two highly effective&#xD;
             contraceptive methods during the study and for six months after discontinuation.&#xD;
&#xD;
          -  Patient must be able (i.e. sufficiently fluent) and willing to complete the quality of&#xD;
             life questionnaires.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy (at doses&#xD;
             more than 10 mg prednisone or equivalent) or any other form of immunosuppressive&#xD;
             therapy within 7 days prior to the first and any dose of trial treatment.&#xD;
&#xD;
          -  Has active autoimmune disease that has required systemic treatment in the past 3 years&#xD;
             (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive&#xD;
             drugs) or history of allogeneic transplantation. Replacement therapy (e.g. thyroxine,&#xD;
             insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary&#xD;
             insufficiency, etc.) is not considered a form of systemic treatment.&#xD;
&#xD;
          -  Must not have received a live vaccine within 30 days of planned start of study&#xD;
             therapy.&#xD;
&#xD;
          -  Patients with known active central nervous system (CNS) metastases and/or&#xD;
             carcinomatous meningitis. Subjects with previously treated brain metastases may&#xD;
             participate provided they are stable (without evidence of progression by imaging for&#xD;
             at least four weeks prior to the first dose of trial treatment and any neurologic&#xD;
             symptoms have returned to baseline), have no evidence of new or enlarging brain&#xD;
             metastases, and are not using steroids for at least 7 days prior to trial treatment.&#xD;
             This exception does not include carcinomatous meningitis which is excluded regardless&#xD;
             of clinical stability.&#xD;
&#xD;
          -  Patients who have experienced untreated and/or uncontrolled cardiovascular conditions&#xD;
             and/or have symptomatic cardiac dysfunction including cardiac ventricular arrhythmias&#xD;
             requiring medication, history of 2nd or 3rd degree atrioventricular conduction&#xD;
             defects) or who have had unstable angina congestive heart failure or myocardial&#xD;
             infarction within the previous year. Patients with a significant cardiac history, this&#xD;
             includes hypertension, even if controlled, should have a LVEF ≥ 50%.&#xD;
&#xD;
          -  Patients with a history of other malignancies unless having undergone curative therapy&#xD;
             (i.e. resection, radiation, etc) and do not require concurrent anticancer therapy.&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to pembrolizumab or any of the other chemotherapy agents.&#xD;
&#xD;
          -  Concurrent treatment with other investigational drugs or anti0cancer therapy.&#xD;
&#xD;
          -  Patients with serious illness or medical condition that would not permit the patient&#xD;
             to be managed according to the protocol including, but not limited to:&#xD;
&#xD;
               -  History of significant neurologic or psychiatric disorder which would impair the&#xD;
                  ability to obtain consent or limit compliance with study requirements.&#xD;
&#xD;
               -  Active infection requiring systemic therapy; (including any patient known to have&#xD;
                  active hepatitis B, hepatitis C or human immunodeficiency virus (HIV) [note:&#xD;
                  testing in asymptomatic patients is not required] or tuberculosis).&#xD;
&#xD;
               -  Known history of, or any evidence of active, non-infectious pneumonitis.&#xD;
&#xD;
               -  Any other medical conditions that might be aggravated by treatment.&#xD;
&#xD;
               -  Serious or non-healing wound, ulcer, or bone fracture.&#xD;
&#xD;
          -  Patients with evidence of interstitial lung disease.&#xD;
&#xD;
          -  Patients with severe/uncontrollable tumor pain that requires radiation prior to&#xD;
             starting on systemic therapy.&#xD;
&#xD;
          -  Pregnant or lactating women. (N.B.: All women of childbearing potential must have a&#xD;
             negative pregnancy test within 72 hours prior to registration).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Quincy Chu</last_name>
    <role>Study Chair</role>
    <affiliation>Cross Cancer Institute, Edmonton Alberta Canada</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francesco Perrone</last_name>
    <role>Study Chair</role>
    <affiliation>National Cancer Institute of Naples, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laurent Greillier Marseille</last_name>
    <role>Study Chair</role>
    <affiliation>Hopital Nord, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BCCA - Cancer Centre for the Southern Interior</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y 5L3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BCCA - Fraser Valley Cancer Centre</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3V 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CancerCare Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Centre at Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Regional Cancer Program</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital Research Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUM-Centre Hospitalier de l'Universite de Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 3E4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Research Institute of the McGill University</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Institute of Cardiology and</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allan Blair Cancer Centre</name>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <zip>S4T 7T1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP Hopital Tenon</name>
      <address>
        <city>Paris</city>
        <state>Cedex 20</state>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Alexis Vautrin</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <state>Cedex</state>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Dupuytren</name>
      <address>
        <city>Limoges</city>
        <state>FR</state>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital du Scorff</name>
      <address>
        <city>Lorient</city>
        <state>FR</state>
        <zip>56100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lyon URCOT</name>
      <address>
        <city>Pierre-benite</city>
        <state>FR</state>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Rennes - Hopital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <state>FR</state>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave-Roussy</name>
      <address>
        <city>Villejuif</city>
        <state>FR</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Tours - Hopital Bretonneau</name>
      <address>
        <city>Tours Cedex</city>
        <state>Tours Cedex 9</state>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU - Angers</name>
      <address>
        <city>Angers</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Jean Minjoz</name>
      <address>
        <city>Besancon Cedex</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boulogne - Ambroise Pare</name>
      <address>
        <city>Boulogne</city>
        <zip>92104</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Caen - CHU</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clermont-Ferrand - CHU</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal de Creteil</name>
      <address>
        <city>Creteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier du Mans</name>
      <address>
        <city>Le Mans</city>
        <zip>72037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lille - Hopital Calmette</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marseille - Hopital Nord</name>
      <address>
        <city>Marseille</city>
        <zip>13915</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montpellier 34298</city>
        <zip>CEDEX 5</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Mulhouse</name>
      <address>
        <city>Mulhouse</city>
        <zip>68070</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Rene Gauducheau</name>
      <address>
        <city>Nantes</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Bichat</name>
      <address>
        <city>Paris</city>
        <zip>75877</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nouvel Hopital Civil Hopitaux</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHITS Toulon Sainte Musse</name>
      <address>
        <city>Toulon</city>
        <zip>83056</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Larrey</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncologia SS Antonio e Biagio Alessandria</name>
      <address>
        <city>Alessandria</city>
        <state>AL</state>
        <zip>15121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera San Giuseppe Moscati</name>
      <address>
        <city>Avellino</city>
        <state>AV</state>
        <zip>83100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Ospedale Oncologico Giovanni Paolo II</name>
      <address>
        <city>Bari</city>
        <state>BA</state>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncologia Medica Humanitas Gavazzeni Bergamo</name>
      <address>
        <city>Bergamo</city>
        <state>BG</state>
        <zip>24125</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Garibaldi Nesima</name>
      <address>
        <city>Catania</city>
        <state>CT</state>
        <zip>95123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Clinico Humanitas</name>
      <address>
        <city>Rozzano (MI)</city>
        <state>Lombardia</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncologia Medica IRCCS Arcispedale Maria</name>
      <address>
        <city>Reggio Emilia</city>
        <state>RE</state>
        <zip>42123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituti Fisioterapici Ospitalieri IFO Istituto</name>
      <address>
        <city>Rome</city>
        <state>RM</state>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PO A Perrino ASL Brindisi - UOC Oncologia Medica</name>
      <address>
        <city>Brindisi</city>
        <zip>72100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOU Policlinico Vittorio Emanuele UOC di Oncologia</name>
      <address>
        <city>Catania</city>
        <zip>95125</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. di Oncologia Ospedale Villa Scassi</name>
      <address>
        <city>Genova</city>
        <zip>16149</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intstituto Scientifico Romangnolo</name>
      <address>
        <city>Meldola</city>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O.C. di Oncologia U.L.S.S. 13</name>
      <address>
        <city>Mirano</city>
        <zip>30035</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Rilievo Nazionale</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dott. Fortunato Ciardiello,Cattedra Oncologia Medica</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O.S.D. Day Hospital Oncologico-Pneumologico</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unita Sperimentazioni Cliniche Istituto per lo</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda USL di Piacenza, Ospedale Gugliemimo Salieto</name>
      <address>
        <city>Piacenza</city>
        <zip>29100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 24, 2016</study_first_submitted>
  <study_first_submitted_qc>May 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2016</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Mesothelioma, Malignant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

